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It has been proposed that endothelial dysfunction is due to the excessive degradation of
nitric oxide (NO) by oxidative stress. The enzyme heme-oxygenase (HO) seems to exert
a protective effect on oxidative stress in the vasculature, both in animal models and in
humans. The objective of this study is to evaluate the effects of inhibition or activation
of HO on endothelial function in mesenteric small resistance arteries of spontaneously
hypertensive rats (SHR). Six SHR were treated with cobalt protoporphyrin IX 50 mg/Kg
(CoPP), an activator of HO; six SHR with stannous mesoporphyrin 30 mg/Kg (SnMP),
an inhibitor of HO, and six SHR with saline. As controls, six Wistar-Kyoto rats (WKY)
were treated with CoPP, six WKY with SnMP, and six WKY with saline. Drugs were
injected in the peritoneum once a week for 2 weeks. Systolic blood pressure (SBP) was
measured (tail cuff method) before and after treatment. Mesenteric small resistance
arteries were mounted on a micromyograph. Endothelial function was evaluated as a
cumulative concentration-response curve to acetylcholine (ACH), before and after pre-
incubation with N(G)-methyl-L-arginine (L-NMMA, inhibitor of NO synthase), and to
bradykinin (BK). In SHR treatment with CoPP, improved ACH-and BK-induced vasodi-
latation (ANOVA p < 0.001) and this improvement was abolished by L-NMMA
(ANOVA p < 0.001). SnMP was devoid of effects on endothelial function. In WKY, both
activation and inhibition of HO did not substantially affect endothelium-mediated
vasodilatation. The stimulation of HO seems to induce an improvement of endothelial
dysfunction in SHR by possibly reducing oxidative stress and increasing NO availability.
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Introduction
The endothelium plays a pivotal role in transducing and modulating biochemical, humoral,
and mechanical stimuli coming from the vascular lumen. It controls vascular permeability,
circulating cells adhesion, and smooth muscle cells contraction and dilatation, thus modu-
lating vascular tone.
Arterial hypertension, diabetes mellitus, dyslipidemia, and other cardiovascular risk fac-
tors may modify the cell redox state in the vessel lumen and wall and may trigger the onset
of endothelial dysfunction (1–3). An increase in oxidative stress observed in these patholog-
ical conditions is driven by an excess production of reactive oxygen species, thus leading to
vascular inflammation and an excessive degradation of nitric oxide. In large arteries, alter-
ations of endothelial function promote atherosclerotic processes (4). In small arteries
(< 350 μm of lumen diameter), the endothelium exerts a key role in the imbalance between
vasoconstriction and vasodilatation and may induce growth responses in the tunica media of
the vessels (5,6). Consequently, endothelial dysfunction and damage may theoretically have
an impact on vascular smooth muscle cell structure and function, intercellular matrix pro-
teins, and, hence, on small artery remodelling, although this point is still controversial (7).
It has been demonstrated previously that the heme/heme-oxygenase system may have
relevant antioxidant properties (4,8). Heme oxygenase (HO) is a cytoprotective enzyme
that degrades heme (a compound with potent oxidant properties), generating carbon mon-
oxide (CO), a gas with vasodilator and anti-inflammatory properties, bilirubin (that is
derived from biliverdin and has antioxidant effects), and iron (sequestered by ferritin).
Heme oxygenase exists in two isoforms: the first one, HO-1, is an inducible enzyme that
catalyzes the degradation of heme in the previously mentioned catabolites, while second,
HO-2 is the constitutive form of the enzyme. Carbon monoxide and biliverdin may mediate
the protective effect of HO-1 in terms of anti-inflammatory, anti-apoptotic, and anti-
proliferative actions (8). Carbon monoxide may stimulate soluble guanylyl-cyclase or
may open calcium-activated K+ channels inducing relaxation of smooth muscle cells,
while biliverdin and its derivative bilirubin are potent antioxidant compounds, and may
inhibit lipid peroxidation, reduce oxidative stress, and increase half-life of nitric oxide (8).
On this basis, HO seems to exert a protective effect toward oxidative stress in the vasculature,
both in animal models and in humans.
Spontaneously hypertensive rats (SHR) represent an animal model of genetic hyper-
tension that from 4 to 12 weeks of age simultaneously develop high blood pressure values
and endothelial dysfunction in several vascular districts, including mesenteric small resis-
tance arteries (9,10). However, no data are presently available about the effects of a phar-
macological modulation of the HO system on endothelium-dependent functional responses of
small resistance arteries in SHR.
Therefore, we considered it important to investigate the effects of the in-vivo inhibi-
tion or activation of HO on endothelial function in mesenteric small resistance arteries of
SHR using a precise and reliable in-vitro ex vivo micromygraphic technique.
Materials and Methods
Thirty-six male rats were included in the study. They were 18 Wistar-Kyoto normotensive
control rats (WKY) and 18 SHRs at 12 weeks of age. The animals were obtained from
562 E. Porteri et al.
Charles River Laboratory (Calco, Italy). All the following procedures were in accordance
with the institutional guidelines. The rats were housed two to a cage in a room in which
the temperature was controlled from 23°C to 25°C and a 12-hour light/dark cycle was
maintained. Food (standard laboratory chow) and water were supplied ad libitum. Animals
were treated by injections of cobalt protoporphyrin IX (CoPP), which is an inducer of HO,
at a dose of 50 mg/Kg of body weight, or stannous mesoporphyrin (SnMP), an HO inhibitor,
at a dose of 30 mg/kg, or saline. Treatments were injected into the peritoneum once a
week for 2 weeks. The animals were subdivided in six groups (six animals per group):
group 1: SHR treated with cobalt protoporphyrin IX (SHR-CoPP); group 2: SHR treated
with stannous mesoporphyrin (SHR-SnMP); group 3: SHR rats treated with saline (SHR
Saline); group 4: WKY treated with CoPP (WKY-CoPP); group 5: WKY treated with
SnMP (WKY-SnMP); group 6: WKY treated with saline (WKY Saline). CoPP and SnMP
were obtained from Sigma-Aldrich, Milan, Italy.
Blood Pressure Measurement
Systolic blood pressure (SBP) was measured noninvasively (tail cuff method, IITC Life
Science Instruments, Woodland Hills, CA) in conscious rats before and after treatment. In
our laboratory, the average coefficient of variation of the plethysmographic SBP measure-
ment was 5.23% (16 rats, 10 measurements in each rat in a single session).
Small Arteries Evaluation
Seven days after the last administration of the drugs, the animals were killed by decapita-
tion and the small intestine were dissected promptly. Four mesenteric small arteries
(second-third branch) feeding the first part of ileum (about 10 cm from the pylorus) were
isolated. The remaining part of the mesenteric tree was immediately frozen for immuno-
histochemical studies. At the same time, mesenteric small arteries were mounted as ring
preparation on an isometric myograph (410 A, Danish Myo Technology, Aarhus, Denmark)
according to Mulvany’s technique (9,10). The vessels segments (100 to 280 μm average
diameter in relaxed conditions, 2 mm long) were excised free of connective and adipose
tissue and two stainless steel wires of 40 μm diameter were treaded through the lumen.
Data from four different vessels from each rat were averaged, to provide one observation
per rat. Details about the micromygraphic technique of evaluation of small artery mor-
phology were previously reported (10–13).
Endothelial Function Evaluation
Endothelial function was evaluated by testing the vasodilator responses to acetylcholine
and bradykinin. We decided to explore endothelial function by using two different endot-
helial agonists in order to have a wider picture of endothelium-dependent responses, as
previously done in similar studies (3,14,15).
Vessels were precontracted with norepinephrine 10−5 mol/L for 2 minutes. A
concentration-response curve to acetylcholine was performed at the following cumula-
tive concentrations: 10−9, 10−8, 10−7, 10−6, 10−5 mol/L. The same protocol was repeated
after preincubation with N(G)-methyl-L-arginine (L-NMMA, inhibitor of nitric oxide
synthase) at the concentration of 300 μmol/L. A concentration-response curve to brady-
kinin was also performed at the following cumulative concentrations: 10−10, 10−9, 10−8,
10−7, 10−6 mol/L.
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Endothelium-independent vasodilatation was evaluated by exposing the vessels to
increasing concentrations of sodium nitroprusside, after norepinephrine precontraction.
The dose-response curve to sodium nitroprusside was performed at the following cumula-
tive concentrations: 10−9, 10−8, 10−7, 10−6, 10−5 mol/L. Vasodilator responses were
expressed as the percent decrease of the wall tension obtained with norepinephrine pre-
contraction. HO-1 expression in mesenteric small resistance arteries was then evaluated
by immunohistochemistry.
HO-1 Immunohistochemistry
After freezing, serial sections of small mesenteric arteries were cut by a cryostat (8-μm tick)
and placed in gelatine-coated slides. The sections were immersed in 3% hydrogen peroxide in
methanol for 30 min to block the endogenous peroxidase activity. The sections were then
incubated with normal goat serum (10% in PBS containing 0.1% Triton X-100) for 60 min,
and successively with rabbit polyclonal anti-HO-1 (Stressgen, Victoria, British Columbia
CANADA) diluted 1:500 in PBS, containing 3% normal goat serum and 0.1% Triton X-100,
for 1 at room temperature and overnight at 4°C. After incubation in the primary antiserum, the
sections were sequentially incubated in biotinylated goat anti-rabbit immunoglobulins and avi-
din-biotin peroxidase complex (Vector Labs, Burlingame, CA) and were stained by immersing
the slides in a solution of 0.05% 3.3-diaminobenzidine tetrahydrochloride (DAB) (Sigma, St.
Louis, MO) and 0.03% hydrogen peroxide. All slides were dehydrated and mounted by DPX
(Sigma). Specificities of antibodies labelling were investigated using appropriate controls,
incubating the tissue sections with non-immune rabbit serum instead of the primary antiserum.
Statistical Analysis
The results are expressed as mean ± SD. A student’s t-test analysis with Bonferroni’s cor-
rection for multiple comparison was used for comparison of differences of means among
different groups. All investigated variables were normally distributed. Statistical signifi-
cance of differences among experimental groups in the vasodilator responses to acetylcholine
and bradykinin was estimated using a two-way analysis of variance (ANOVA) for
repeated measures. A p-value less than 0.05 was considered statistically significant.
Results
Blood Pressure
Systolic blood pressure values in SHR and WKY at baseline and after treatment (12 and 14
weeks of age) are reported in Figure 1. Treatment with CoPP and SnMP significantly
decreased SBP in SHR in respect with saline (161.8 ± 15.7 and 163.1 ± 20.5 mm Hg, respec-
tively, versus 186.1 ± 8.5 mmHg, p < 0.05). Blood pressure values after treatment compared to
baseline were significantly different only in the WKY group treated with SnMP. In every case,
SBP values observed in SHR, both before or after any treatment, were significantly different
(p < 0.001) in respect to blood pressure values observed in WKY, before or after any treatment.
Endothelial Function
A significant reduction in the vasodilator responses to acetylcholine and bradykinin was
observed in SHR treated with saline compared with WKY treated with saline (ANOVA
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p < 0.001) (Figures 2 and 3). In SHR treated with CoPP, a significant improvement in the
response to acetylcholine and bradykinin was observed (ANOVA p < 0.001 vs. SHR
treated with saline or SnMP), while SnMP was devoid of effect, when compared to saline
(Figures 2 and 3). In WKY, no difference in the concentration-response curve to acetyl-
choline and bradykinin between saline, CoPP, or SnMP was observed. Preincubation with
L-NMMA did not significantly modify the concentration-response curve to acetylcholine
in SHR treated with saline and in SHR treated with SnMP, while in SHR treated with
CoPP, a significant reduction in the vasodilator response was observed (ANOVA p < 0.001 vs.
no preincubation with L-NMMA; ANOVA p < 0.01 vs. WKY treated with saline after
preincubation with L-NMMA, ANOVA p = NS vs. SHR treated with saline after preincu-
bation with L-NMMA), suggesting a restoration of the bioavailability of nitric oxide (NO)
(Figure 2). In WKY treated with saline, CoPP or SnMP, incubation with L-NMMA
slightly, but significantly reduced vasodilatation to acetylcholine (ANOVA < 0.05 in each
case).
Endothelium-independent vasodilatation (concentration-response curves to sodium
nitroprusside) was not significantly different among the groups studied (data not shown).
HO-1 Immunoreactivity
Semi-quantitave analysis of HO-1 vascular content is reported in Table 1. HO-1 immu-
noreactivity appeared as brown spots and it was localized in the cytoplasm of endothelial
and vascular smooth muscle cells. HO-1 positive cells were also found in the adventitia. In
the WKY rats, we observed a moderate staining in the tunica intima, the media, and the
adventitia (Figure 4). In SHR, the HO-1 staining was similar to that found in WKY (Table 1,
Figure 4), although brown staining appeared more evident within the tunica media than in
Figure 1. Systolic blood pressure (BP) values in SHR and WKY before (10 weeks of age) and after
treatment (12 weeks of age) (saline, CoPP, SnMP). Values are expressed as mean ± SD. *p < 0.05
vs. SHR after saline treatment; # p < 0.05 vs. WKY SnMP at baseline (Basal), before treatment.
Systolic blood pressure before and after treatment
100
120
140
160
180
200
mm Hg
Basal BP
BP after treatment
*
*
#
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the endothelial cells (Table 1, Figure 4). The administration of CoPP increased HO-1
immunostaining in the tunica intima, media, and adventitia of WKY and SHR rats (Table 1,
Figure 4). The administration of SnMP did not induce changes in the immunohistochemical
pattern of HO-1 immunoreactivity both in WKY and SHR, in respect to saline.
Discussion
Our study demonstrated that endothelium-dependent vasodilatation in mesenteric small
resistance arteries from adult SHR was improved after treatment with the HO inducer
cobalt protoporphyrin IX. On the contrary, stannous mesoporphyrin, which inhibits HO,
did not modify the vessels’ response to acetylcholine and bradykinin, probably because it
was maximally impaired. Since the inhibitory effect of L-NAME is present when the NO
production is maintained or restored, our interpretation is that in SHR treated with CoPP,
basal vasodilation to acetylcholine is improved compared to basal saline (Figure 2, left
panel), while L-NAME is able to decrease acetylcholine-dependent responses in CoPP-
treated SHR, thus suggesting a restored bioavailability of NO.
A normal microvascular function is maintained provided that anatomical integrity of
the endothelial cells and normal vasodilator and contractile responses of vascular smooth
muscle cell are present. Spontaneously hypertensive rats represent an experimental model
of genetic hypertension which shows several pathological aspects similar to those of
human hypertension, namely, an increase in the renin-angiotensin system activity, insulin
resistance, dyslipidemia, etc. Young SHRs rapidly develop hypertension and endothelial
dysfunction, which are clearly established at the age of 12 weeks (10). Our data demonstrated
Figure 2. Left panel: concentration-response curve to acetylcholine (from 10−9 to 10−5 mol/L): %
relaxation after precontraction with norepinephrine 10−5 mol/L. Right panel: concentration-response
curve to acetylcholine (from 10−9 to 10−5 mol/L) after preincubation with L-NAME 300 μmol/L. See
text for significance between curves. Abbreviations: WKY SnMP-Wistar-Kyoto rats treated with
SnMP (n = 6). WKY CoPP-Wistar Kyoto rats treated with CoPP (n = 6). SHR SnMP-spontaneously
hypertensive rats treated with SnMP (n = 6). SHR CoPP-spontaneously hypertensive rats treated
with CoPP (n = 6). SHR Saline-spontaneously hypertensive rats treated with saline (n = 6). WKY
Saline-Wistar-Kyoto rats treated with saline (n = 6).
–100
–80
–60
–40
–20
0
20
%
WKY SnMP
WKY CoPP
SHR CoPP
SHR SnMP
SHR Saline
WKY Saline
ANOVA p < 0.001 ANOVA p < 0.001
Acetylcholine (Mol/l)
10–9 10–8 10–7 10–6 10–510–9 10–8 10–7 10–6 10–5
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that a 2 week stimulation of HO-1 is able to induce a significant improvement in endothelium-
dependent vasodilatation and this effect is completely abolished by preincubation with the
nitric oxide synthase inhibitor L-NMMA. On the other hand, the inhibition of HO-1 activity
does not modify the vasodilator response induced by acetylcholine both in SHR and
WKY. These results confirm the relevance of the heme/heme oxygenase system in the
Figure 3. Concentration-response curve to bradykinin (from 10−9 to 10−5 mol/L) of rat mesenteric
small arteries: % relaxation after precontraction with norepinephrine 10−5 mol/L. Abbreviations:
WKY SnMP-Wistar-Kyoto rats treated with SnMP (n = 6). WKY CoPP-Wistar Kyoto rats treated
with CoPP (n = 6). SHR SnMP-spontaneously hypertensive rats treated with SnMP (n = 6). SHR
CoPP-spontaneously hypertensive rats treated with CoPP (n = 6). SHR Saline-spontaneously hyper-
tensive rats treated with saline (n = 6). WKY Saline-Wistar-Kyoto rats treated with saline (n = 6).
Saline vs. SHR SnMP.
–50
–40
–30
–20
–10
0
10
%
WKY CoPP
WKY SnMP
SHR CoPP
SHR SnMP
SHR saline
WKY saline
ANOVA p<0.01
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Table 1
HO-1 immunoreactivity in the mesenteric small resistance arteries of SHR and WKY 
treated with saline, CoPP, or SnMP
HO-1 
endothelium
HO-1 tunica 
media
HO-1 tunica 
adventitia
SHR Saline n = 6 + ++ ++
SHR CoPP n = 6 ++ +++ +++
SHR SnMP n = 6 + ++ +++
WKY Saline n = 6 ++ ++ ++
WKY CoPP n = 6 +++ +++ +++
WKY SnMP n = 6 ++ ++ ++
Abbreviations: WKY SnMP-Wistar-Kyoto rats treated with SnMP; WKY CoPP-Wistar
Kyoto rats treated with CoPP; SHR SnMP-spontaneously hypertensive rats treated with SnMP;
SHR CoPP-spontaneously hypertensive rats treated with CoPP; SHR Saline-spontaneously
hypertensive rats treated with saline; WKY Saline-Wistar-Kyoto rats treated with saline.
Semi-quantitative data: (−) negative; (+/−) very weak; (+) weak; (++) moderate; (+++) strong.
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vascular function control and provide an insight into mechanisms that may explain protec-
tive effects of HO-1 on hypertensive complications.
It is well known that HO-1 is extremely effective in inhibiting vascular smooth
muscle cell growth, and hence, the development of arteriosclerotic processes (16–20).
However, the potential clinical application of the stimulation of HO-1 by substances
such as cobalt protoporphyrin IX or by gene therapy is still problematic (21,22). In con-
trast, the products engendered by HO-1 in the degradation of heme, including CO (23)
and biliverdin/bilirubin that mediate the actions of HO-1, seem to be close to a potential
application in the clinical setting (24). In fact, biliverdin and bilirubin may inhibit
injury-induced vascular smooth muscle cell proliferation and thus prevent narrowing of
the vascular lumen in patients with arteriosclerotic lesions associated with chronic graft
rejection and balloon injury (23).
Three lines of evidence suggest that bilirubin may have desirable properties. First,
bilirubin is a very potent antioxidant that may efficiently scavenge chemically generated
peroxyl radicals (25), and therefore, attenuate vascular endothelial activation and dysfunc-
tion (26). Second, several studies have shown that individuals with high-normal or slightly
above-normal levels of bilirubin have a lesser incidence of atherosclerosis-related diseases
than individuals with low-normal levels (27). However, these findings do not necessarily
implicate bilirubin as the protective agent given that they are based solely on association
studies. Finally, the administration of bilirubin or its precursor biliverdin to rodents can
suppress unwanted reactions such as ischemia/reperfusion injury (23,28) and allograft
rejection (23,29). However, up until now, few studies have addressed the issue of the role
of biliverdin/bilirubin in the prevention of microvascular structural alterations, and in the
development of organ damage in hypertension.
Figure 4. Immunohistochemical staining of HO-1 of rat mesenteric small arteries. The immunore-
activity appeared as brown spots. Arrows indicate HO-1 immunoreactivity within the endothelial
cells. Bar-20 μm.
SHR
CoPP SalineSnMP
WKY
SnMP SalineCoPP
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Recently, Wang et al. showed that during a short period of treatment (3 weeks), the
activation of HO-1 with hemin promotes the regression of vascular structural alterations
and normalizes blood pressure values until 9 months after the end of the treatment (30). In
a previous study (31), the same authors provided evidence that 8-week SHRs with higher
blood pressure values than age-matched WKY have lower basal expression levels of HO-1
and relative transmitters. The dysfunction of the HO system was already present in a pre-
hypertensive stage and hence seems not a consequence to the development of hypertension.
The stimulation by hemin of HO is able to induce a prevention of the development of
hypertension after a short treatment (4 days) started very early, at 7 weeks of age. In fact,
20-week-old SHRs are resistant to HO induction and show no reduction of blood pressure
values (31). In our study, we could not test the effect of a longer administration of drugs
modulating the HO system, since intraperitoneal administration cannot be extended
beyond a couple of weeks. After a short-term treatment with the activator of HO, we could
observe a reduction, but not a complete normalization, of blood pressure values. On the
contrary, Wang et al. (30) observed a normalization of blood pressure values after 2 weeks
of continuous infusion by a subcutaneous hemin-releasing pump; however, in a previous
work, the same authors found a reduction (not a normalization) of blood pressure values
after intraperitoneal treatment (32). The efficacy of slow release systems could obviously
be more effective compared to an intraperitoneal bolus which could have a rather suboptimal
peak–trough effect. These aspects may partly explain the different results in terms of
blood pressure and vascular morphology between our study and Wang et al’s (30). In fact,
we could not observe any improvement in structural alterations of small arteries of SHRs
treated with CoPP (data not shown). Nevertheless, in our study a significant reduction in
SBP was accompanied by a normalization of the endothelial function.
The patho-physiological mechanisms underlying our findings are not clear. Obvi-
ously, some of the end-products of HO-1 activation, mainly bilirubin and CO, could
exert some beneficial effects on vascular function. HO-1 activators are able to increase
bilirubin and biliverdin, which are powerful antioxidants and can thus improve endothe-
lial function by lowering oxidative stress reactions (26,33) and increase the half-life of
nitric oxide (8). In our study, the positive effect of CoPP on acetylcholine-induced
vasodilatation was abolished by the preincubation with the inhibitor of the inducible
nitric oxide synthase L-NMMA. Therefore, it seems probable that an interaction
between CO and nitric oxide is involved in the observed effect: both systems contribute
to vascular tone control and play a role in controlling vascular tone. However, we can-
not exclude that other modulator processes, closely related to a HO/CO system, could be
involved in the observed improvement of endothelial function. Heme-oxygenase inducers
are also implicated in the cytochrome P-450 dependent arachydonic acid metabolic
pathway (34). Since heme constitutes the prosthetic moiety of many cytochrome enzymes
by degrading heme, HO controls the quantity of these enzymes, including cytochrome
P-450 monooxygenase.
Finally, a possible limitation of the study is related to the dose of CoPP used in our
study. It was previously proposed that some alteration in the cellular CYP340 content may
occur, with possible alterations in the tyroid function (35). However, no sign of CoPP tox-
icity was observed in our study, probably due to the relative short duration of the treat-
ment. A second limitation is the lack of measurements of HO activity and HO isoforms
protein quantification, considering that immunohistochemistry represent a semi-quantitatve
approach. However, our study was aimed at evaluating vascular functional responses,
while data about effect of CoPP on HO levels were obtained previously (increased levels
of HO-1 mRNA, protein, and activity) (36).
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In our study, SnMP did not worsen endothelium-dependent responses in WKY.
Although this finding is partly surprising, it is possible that WKY rats may be resistant to
the adverse effects of SnMP, through an activation of controregulatory and protective
mechanism. In both SHRs and WKYs, short-term treatment with SnMP induced a reduction
of blood pressure. Since the drug passes the blood-brain barrier, it is possible that central
mechanisms (reduction in sympathetic nervous system activity or a Adreno Cortico
Tropic Hormone (ACTH) release) may be involved in the observed findings (37). The
decrease in blood pressure have not influcenced our results in terms of vascular functional
responses, since in our study they have been evaluated in vitro, with no actual pressure or
flow. Finally, no difference in HO immunoreactivity between SHRs and WKYs was observed
in our study, probably due to the relative lack of sensitivity of our semi-quantitative approach.
In conclusion, as previously mentioned, the HO/CO metabolic pathway is believed to
be involved in the regulation of basal tone of resistance blood vessels and also in the devel-
opment of vascular remodeling. Modulation of HO by appropriate drugs may improve
endothelium-dependent dilatation of small arteries, reduce blood pressure and oxidative
stress in animal models, and may also delay the progression of human atherosclerotic
lesions. Therefore, possible clinical application of pharmacological modulation of an HO
system is of primary interest and importance. Our data provide a contribution in this regard.
Therefore, our results indicate that the stimulation of HO seems to induce an
improvement of endothelial function in SHRs, possibly by reducing oxidative stress and
increasing NO availability. Further studies are needed to precisely elucidate the underly-
ing mechanism, as well as the potential clinical application of drugs modulating HO.
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